1/ Thanks Larry (and all co-authors) and @AjHematology for this! RW data for a frequent q in my own #MMsm clinic, namely patients starting teclistamab disappointed by D30 results after hearing "Median time to 1st response 1.1 mo"... Can we predict delayed response conversion?

Fantastic event w discussion, debates, & exchange of knowledge, ideas, and opinions at the Kyle Barlogie #PlasmaCellDisorders symposium #MMSM @MSK_DeptOfMed @MayoClinic #MedTwitter #MedEd @szusmani @VincentRK @myelomaMD @FrancescoMaura4 @UrviShahMD @sridevirajeeve & many others

MRD vs No MRD guided treatment for Myeloma: A great debate b/w @szusmani (yes) vs @End_myeloma (no) and discussion by @VincentRK on MRD driven treatment in Multiple Myeloma Kyle Barlogie Plasma Cell Disorders Symposium #MMSM #MedTwitter #MedEd #AgreeToAgree

NDMM diagnostics and Risk Assessment : Great talk by @End_myeloma on MRD driven treatment adaptations in Multiple Myeloma Kyle Barlogie Plasma Cell Disorders Symposium #MMSM #MedTwitter

A great day here in Minnesota for discussion, debates, and exchange of knowledge, ideas, and opinions at the 2nd Annual Kyle Barlogie #PlasmaCellDisorders symposium. #MMSM @MSK_DeptOfMed @MayoClinic #MedTwitter #MedEd

➡️40% of pts with LCMM had t11;14. I have historically seen early + deep responses with LCMM and slow + plateaued responses with t11;14. It would be interesting to see if LCMM with t11;14 still has early and deep RR @ZanwarSaurabh @RahulBanerjeeMD #mmsm

Looking forward to this event. There is still time to register and learn from the giants of Myeloma https://t.co/32XkiG1iJ1 Summary - 2nd Annual Kyle Barlogie Plasma Cell Disorders Symposium #mmsm #MedTwitter #MedEd @MayoClinic @MSKCancerCenter

Excellent review in @NEJM by @VincentRK and @myelomaMD ➡️No need for testing for MGUS in asymptomatic with no family hx ➡️No need for BMBx and imaging in low risk MGUS ➡️Abnormal light chains and K/L ratio should be adjusted for age and renal function #MMSM #MGUS #MedTwitter

Presented at #IMS25, now in @BloodPortfolio 👉22% of NDMM HR by new IMWG Consensus Genomic model 👉CD38 Ab & ASCT had ⬆️⬆️PFS for both SR and HR 👉If no HR genomics, ⬆️ B2M had similar outcomes as normal B2M #MMSM #MedTwitter @ASchavgoulidze 👏👏

Best of Myeloma Highlights, Debates, Discussions!! ➡️Really excited about this stellar line up of Myeloma experts at 2nd Annual Kyle Barlogie Symposium in MN ➡️A little nervous about debating against transplant.. #MedTwitter #MMSM #MayoClinic #msk

I agree. Some of the prelim 'teasers' on BsAb in NDMM were exciting but response criteria was 💡💡 of #IMS25. Relying on SUV on PET rather than size of lesion made it clear for imaging response although DS ≤3 rather than DS <4 would have been more aligned with Lymphoma reads

👉👉For late line relapse where bridging options are limited, Talquetamab can be a great holding/bridging therapy. 👉👉Need to study BCMA / GPRC5d expression at relapse post CAR T, T cell phenotype, CAR T expansion @bhemato #MMSM #MedTwitter

Thank you @beatalleukemia great to see you! so fun to meet @Brutus_Buckeye and see @OhioStateFB stadium @OSUCCC_James @OSUHematology

➡️Not all PGNMID are MGRS ➡️If BM clone neg by RACE-RepSeq, kidney deposits are polyclonal on IF, suggesting infectious trigger, rather than B-cell disorder requiring chemotherapy #mmsm https://t.co/YZmmJ3HsVI

#IMS25: Plenary session: Linker SMM1:Linvo in Smoldering Myeloma. n=24, weekly step up dosing, 40% HR by 20/2/20 High ORR but CRS 40%, hypogamma 30%, all Gr infection 80% Smoldering MM trials need to focus on HR pts, need composite end points of infection free-PFS #MMSM

#IMS25: oral abstract: @szusmani presenting TANDEMM (MCARH125+MCARH109) targeting BCMA and GPRC5d CAR T for RRMM High and durable responses Differential expansion of CAR T cells based on antigen expression

#IMS25: late breaking abstract: PRO and HRQOL better in patients achieving MRD neg responses in Perseus and Cephesus for NDMM; there is value in pushing quads in these patients. Can we apply the same for DaraTecVR in MAJesTEC-5 w G3 infection 33%?

#IMS25: Late breaking abstract; Adam Cohen presenting on cevostamab consol post Ciltacel, 8 cycles, q3w, majority with MRD negativity, ~15% immune AE. Similar trials at MGH and MSK are evaluating post idecel Elra and Talq (6m) to improve outcomes

#IMS25: @AjayNookaMD presenting on Bela Pom Dex as maintenance in HR NDMM, n=25, 75% HR CG Bela 1.9 mg/kg q12w Early and deep MRD neg responses 80% with blurry vision with 1 DLT